drugset / Trial / NCT03120962

Effect of Early Use of Oxycodone During the Acute Phase of Herpes Zoster on Preventing Postherpetic Neuralgia

NCT03120962

RandomizedParallel-groupOpen-labelTreatment

Summary

Postherpetic neuralgia (PHN) which persists more than 90 days after the resolution of the acute shingles episode is the most common complication of herpes zoster. The continued pain or paresthesia not only affects patient quality of life, but also causes physical disability, emotional distress and social isolation. Conventional treatments for PHN are only partially work in some patients or not work at all in others. Once PHN presences, it is often refractory to the treatment, therefore, it is important to prevent the occurrence of PHN. In the study, the investigators want to identift whether the additional use of oxycodone therapy to current standard treatment in acute herpes zoster patients will decrease the incidence of post-herpetic neuralgia.

Timeline

Start
2017-05
Primary completion
2020-05
Completion
2020-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Oxycodone Other / unclassified 20 mg
Background Famciclovir Small molecule 500 mg
Background Gabapentin Small molecule 1800 mg